Caribou Biosciences (CRBU) Liabilities and Shareholders Equity (2020 - 2025)
Caribou Biosciences has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $175.4 million for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 44.03% to $175.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $864.9 million through Dec 2025, down 39.83% year-over-year, with the annual reading at $175.4 million for FY2025, 44.03% down from the prior year.
- Liabilities and Shareholders Equity was $175.4 million for Q4 2025 at Caribou Biosciences, down from $195.0 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $462.0 million in Q3 2021 and troughed at $158.4 million in Q2 2021.
- The 5-year median for Liabilities and Shareholders Equity is $372.9 million (2024), against an average of $346.9 million.
- Year-over-year, Liabilities and Shareholders Equity skyrocketed 1127.2% in 2021 and then plummeted 44.03% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $442.4 million in 2021, then dropped by 15.51% to $373.8 million in 2022, then rose by 15.64% to $432.2 million in 2023, then dropped by 27.51% to $313.3 million in 2024, then plummeted by 44.03% to $175.4 million in 2025.
- Per Business Quant, the three most recent readings for CRBU's Liabilities and Shareholders Equity are $175.4 million (Q4 2025), $195.0 million (Q3 2025), and $220.9 million (Q2 2025).